Real-World Data Study Backs Up Ide-cel CAR-T Therapy for Multiple Myeloma

A real-world data (RWD) study published in the Journal of Clinical Oncology found Celgene’s Abecma (ide-cel) CAR-T therapy was both safe and effective in the treatment of multiple myeloma. The data, taken from 196 patients, further back up the results from the Phase II KarMMa trial that helped support the approval of the therapy back in 2021.

According to , “Overall, we observed comparable efficacy and toxicity with ide-cel as reported in the KarMMa trial although 75% of our patients would not have met KarMMa eligibility criteria,” wrote Doris K. Hansen, MD, of the Department of Blood Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, and co-investigators, in the study. The most common reasons for trial ineligibility included inadequate organ function, prior exposure to BCMA-TT, cytopenias, and poor performance status.”

To read more, click here.

(Source: Oncology Nursing News, February 2^nd, 2023)